AOD-9604 FAQ: common questions answered
A growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss.
Also called: AOD9604, Tyr-hGH177-191, LAT8881, LAT-8881, HGH fragment 176-191.
Fat-loss peptides · Modified C-terminal growth-hormone fragment.
- Is AOD-9604 FDA-approved? No approved drug or label. Sponsor self-affirmed food-use GRAS in June 2012; that is not FDA drug approval or approval for injection.
- How do people take it? Under the skin, once daily. Reports often describe 8–12 weeks; no validated course length.. Source: reported by users, not an established dose.
- What's the difference between AOD-9604 and Tirzepatide? AOD-9604: a growth-hormone fragment whose largest obesity trial failed to show meaningful weight loss. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: users hope to add fat loss or overcome a weight plateau.
- Can I take it with Tirzepatide? Users hope to add fat loss or overcome a weight plateau. No controlled human combination trial was found; added benefit and safety are unknown. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named as a growth-hormone fragment; prohibited in and out of competition.
- How long does a mixed vial last? Advice conflicts, including room temperature and refrigeration. No validated home-mixed shelf life was found.
Related to AOD-9604
- Adipotide: A fat-blood-vessel targeting peptide with monkey weight-loss data and kidney toxicity.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks, Health Canada · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024, FDA · 2024
- Low blood sugar (hypoglycaemia), NHS · 2023
- Tailor Made Compounding LLC - 594743 - 04/01/2020, FDA · FDA · 2020
- Allergies, NHS
- Subcutaneous (SQ) injections, MedlinePlus
- Taking warfarin, MedlinePlus
- Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans, Stier H, Vos E, Kenley D · Journal of Endocrinology and Metabolism · 2013
- A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain, Lateral Pharma Pty Ltd · 2023
- A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain, Lateral Pharma Pty Ltd
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.